What is known and objectives: Optimal strategies for treating patients with very advanced relapsed and refractory multiple myeloma (RRMM) have not been clarified.
Case summary: A 80-year-old patient with RRMM experienced extramedullary relapse following treatment with bortezomib, lenalidomide and pomalidomide. However, he achieved very good partial remission after retreatment with lenalidomide.
What is new and conclusion: This report illustrates that patients with very advanced RRMM can still respond to prior therapy even after being exposed and refractory to several agents. Considering the depth or duration of response to prior treatment, "retreatment" may improve the outcome of frail RRMM.
Keywords: bortezomib; extramedullary plasmacytoma; lenalidomide; pomalidomide; relapse and refractory MM (RRMM).
© 2018 John Wiley & Sons Ltd.